The setup sounds simple: a company posts its best operating quarter — revenue up 57%, losses 94% narrower, first positive adjusted EBITDA — and the stock drops. That’s Evolv Technology (NASDAQ: EVLV) in a nutshell.
Q4 2025 results drop March 10, after market close. The stock sits at roughly $5.36, down 26% year-to-date. Analyst consensus puts fair value at $9.13. That’s a 70% gap between where the stock is trading and where the people who cover it think it should be. Something is wrong with either the analysts or the stock. Here’s the case for each.
What Evolv Actually Sells
Evolv makes AI-powered weapons detection systems — the walk-through kind, but faster than traditional airport-style metal detectors. Their flagship product, Evolv Express, uses sensors and machine learning to screen people for concealed weapons without requiring them to stop, empty pockets, or open bags. The Gen2 upgrade adds Evolv eXpedite for bag screening.
As of Q3 2025, they’re screening more than 3 million people per day across over 1,100 customers. Sports venues are the most visible segment — 100+ venues, 60+ sports teams. Charlotte FC (Bank of America Stadium) just renewed and upgraded to Gen2 hardware. Inter Miami CF locked in Evolv as the official fan screening provider for their new 25,000-seat Miami Freedom Park stadium, opening April 4. Shell Energy Stadium in Houston signed on in February. But sports is the marketing; healthcare is the business moat.
Evolv is deployed in 500+ hospital buildings, screening 900,000 hospital visitors and staff per day. On February 26, 2026, the American Hospital Association named Evolv its only Preferred Physical Security Provider in the concealed weapons detection category — a designation that took years to earn and opens procurement doors at institutions that move slowly and don’t switch vendors often.
The Numbers That Don’t Match the Stock Price
Q3 2025 results were genuinely good. Revenue hit $42.9 million, up 57% year-over-year from $27.4 million. Annual Recurring Revenue (ARR) reached $117.2 million, up 25% from $93.7 million a year earlier. Net loss narrowed to just $1.8 million — or $0.01 per share — compared to $30.4 million ($0.19 per share) in Q3 2024. Adjusted EBITDA turned positive at $5.1 million, a 12% margin, versus a $3.0 million loss the year before. Cash on hand: $56.2 million.
For the first nine months of 2025, revenue totaled $107.4 million — up 44% year-over-year. The company raised full-year 2025 guidance to $142–145 million (37–40% growth) and guided 2026 at $160–165 million, with ARR expected to grow at least 20%.
One asterisk worth acknowledging: Q3’s $42.9 million included roughly $7.5 million in items that won’t recur — $3 million from the largest single order in company history, $3 million in IP license fees tied to a distribution model being phased out, and $1.5 million from short-term rental agreements that expired during the quarter. Strip those out and the organic Q3 run rate is closer to $35 million. Q4 should come in around $34.6–37.6 million based on the full-year guide, which is directionally consistent. The market noticed the Q3 noise, and part of the YTD decline reflects that. This pattern isn’t unlike what happened with Lemonade’s record quarter that the market also punished.
The FTC Settlement — And Why 92% of Customers Stayed
In March 2025, the Federal Trade Commission settled a case against Evolv over allegations that the company made false claims about its AI-powered screening accuracy. This was the most serious challenge the company has faced since going public — it raised real questions about customer trust and the product’s actual capabilities.
Here’s what actually happened when the smoke cleared.
Evolv gave all 65 of its K-12 education customers — the segment the FTC was most focused on — a 60-day window to exit their contracts, no questions asked, no penalties. 60 of 65 stayed. The five who left represented $445,000 in ARR — less than 0.4% of Evolv’s current ARR base. Four of those 65 eligible customers actually expanded during the cancellation window, adding 10 new units. Wyoming Valley West School District expanded its fleet by 50% and said publicly it was more than pleased with the results.
You can disagree about what Evolv’s past marketing said about detection accuracy. What those customer decisions say about real-world product value is harder to explain away. If the product genuinely didn’t work, school safety coordinators — who are responsible for kids’ lives — would have taken the free exit.
The Board Move Worth Watching
On February 12, 2026, Evolv appointed Henrik Kühl to its board. Kühl is currently SVP of Strategy and Corporate Development at Axon (NASDAQ: AXON) — the company behind TASER, body cameras, and Axon Cloud for public safety agencies.
Axon has a history of acquiring adjacent public safety technology companies. Having a sitting Axon strategy executive on Evolv’s board is either a governance upgrade or something more strategic. Either way, Axon’s domain expertise validates Evolv’s market.
Q4 and the Real Number to Watch
Results drop March 10 after market close. Based on the $142–145 million full-year guide and $107.4 million through nine months, Q4 revenue should land in the $34.6–37.6 million range. Management also said Q4 would be the first cash-flow-positive quarter in company history — that’s a meaningful operational milestone.
Revenue is almost secondary. The number that matters for the 2026 thesis is exit ARR. If ARR exits Q4 above $125 million, the 20%+ ARR growth guided for 2026 becomes very achievable. If ARR disappointingly flattens, the 2026 revenue guide of $160–165 million needs a serious rethink.
Bull Case
At $5.36 with roughly 180 million shares outstanding, market cap is approximately $965 million. Subtract $56 million in cash and you get an enterprise value of around $909 million against $143 million in guided 2025 revenue — about 6.4x forward EV/Revenue. For a company growing 37–40% and reaching profitability, that’s a reasonable multiple by security software standards.
Analysts have a $9.13 consensus price target. That implies 70% upside from current levels. The stadium deals, AHA designation, and Axon board signal aren’t just contracts — they’re credibility. Hospitals and school districts run multi-year subscription renewals, which means ARR compounds with minimal churn risk. The 2026 small-cap rotation is also a tailwind: IWM is up 5.4% YTD while EVLV has been left behind despite better fundamentals than most of the index.
If Q4 delivers and 2026 guidance holds, the gap between the stock and analyst targets narrows fast. Vanguard recently acquired 1.75 million additional shares — not a guarantee, but meaningful institutional conviction.
Bear Case
The director selling is hard to ignore. Three insider sales happened between December 2025 and February 2026, each at progressively lower prices. Long-tenured director Bilal Zuberi resigned from the board effective February 10, 2026, after 13 years. Insider selling at lower prices — not higher — is a classic distribution signal, and it’s the single most uncomfortable data point for bulls.
The FTC settlement left ongoing compliance obligations. Evolv still needs to demonstrate that the performance claims it makes going forward are substantiated. Any new regulatory friction would reprice the stock immediately.
Q3’s $7.5 million in non-recurring items matters because it inflated the year-over-year growth rate. If organic growth comes in at 25–30% instead of 57%, the valuation narrative changes. The stock isn’t cheap enough to absorb a major guidance cut. This is the same valuation trap that hit HIMS despite its 59% revenue growth — high-growth names with any wobble get punished disproportionately.
Competition isn’t standing still. Athena Security, ZeroEyes, and other AI-based weapons detection startups are raising capital and targeting the same verticals. Evolv’s patent portfolio and customer base create a moat, but the market isn’t winner-take-all.
Verdict
Compelling at $5.36, contingent on March 10. The operating fundamentals are genuinely strong — 92% post-FTC customer retention, $5.1 million adjusted EBITDA, AHA designation, and a real path to $160 million in 2026 revenue. The gap between the stock price and analyst targets is unusually wide for a company performing this well operationally.
The insider selling pattern and Q3’s non-recurring items are the two legitimate reasons to wait. If Q4 confirms organic ARR growth above $125 million and management reaffirms the 2026 guide, the bull case snaps into focus. If ARR stalls or guidance gets trimmed, $5 is not a floor.
Watch March 10. That’s the deciding data point.
This is not financial advice. Do your own research. I hold no position in EVLV.